Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Somedeb Ball, Michael T. Byrne, Melissa A Fischer, Farrukh T. Awan, Ben K. Tomlinson, Tess Stopczynski, Lokesh Patil, Christine J. Gu, Chris Leonardi, Katherine J. Walsh, Gregory Dan Ayers, Ashwin Kishtagari, Kateryna Fedorov, Markus D. Lacher, Joseph Wagner, Sanjay R Mohan, Michael R. Savona

Blood (2024) 144 (Supplement 1): 6012.

https://doi.org/10.1182/blood-2024-209403

Published: 2024

Journal Articles

Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine

Lokesh Patil, Christine J. Gu, Cristina Tognon, Nicola Long, Kara Johnson, Melissa A Fischer, Somedeb Ball, Michael R. Savona, Chris Leonardi, Joseph Wagner, Glenn Michelson, Markus D. Lacher

Blood (2024) 144 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2024-206299

Published: 2024

Journal Articles

A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform

Joseph Wagner, Markus D. Lacher, Christine J. Gu, Christopher Leonardi, Gabriel Mannis

Blood (2023) 142 (Supplement 1): 5952.

https://doi.org/10.1182/blood-2023-186953

Published: 2023

Journal Articles

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Guang-Liang Chen, Pin Guo, Shiyu Jiang, Juan J. Gu, Qunling Zhang, Yizhen Liu, Junning Cao, Xiaonan Hong, Rong TAO, Fangfang Lv

Blood (2022) 140 (Supplement 1): 3790–3791.

https://doi.org/10.1182/blood-2022-156877

Published: 2022

Journal Articles

Targeting BCL-XL to Overcome Anti-CD20 Antibodies and Venetoclax Resistance in Pre-Clinical Model of Diffuse Large B Cell Lymphoma

Juan J. Gu, Jessica Wang, Cory Mavis, Taylor K Mandeville, Pallawi Torka, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 11562–11563.

https://doi.org/10.1182/blood-2022-159120

Published: 2022

Journal Articles

Effect of Mcl-1 Inhibitor, AMG-176, on T Cell Quality and Function

Noah Lemoine, Taylor K Mandeville, Cory Mavis, Kevin Bowman, Juan J. Gu, Francisco Hernandez-Ilizaliturri

Blood (2022) 140 (Supplement 1): 12706–12707.

https://doi.org/10.1182/blood-2022-170122

Published: 2022

Journal Articles

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Juan J Gu, Paola Ghione, Shiyu Jiang, Cory Mavis, Francisco J. Hernandez-Ilizaliturri, Dongmei Ji, Junning Cao, Xiaonan Hong, Xuejun Ma, Qunling Zhang

Blood (2021) 138 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2021-149229

Published: 2021

Journal Articles

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Shipra Goel, Juan J. Gu, Pallawi Torka, Cory Mavis, Suchitra Sundaram, Mirdza Neiders, Lakshmanan Suresh, Long Shen, Vince Ramsperger, Elizabeth A. Griffiths, Brahm Segal, Francisco J. Hernandez-Ilizaliturri, Paola Ghione

Blood (2021) 138 (Supplement 1): 1340.

https://doi.org/10.1182/blood-2021-152738

Published: 2021

Journal Articles

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Blood (2021) 138 (9): 811–814.

https://doi.org/10.1182/blood.2021012443

Published: 2021

Includes: Supplemental data

Journal Articles

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

Juan J Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Suchitra Sundaram, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-137812

Published: 2020

Journal Articles

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Suchitra Sundaram, MD, Cory Mavis, MSc, Juan J Gu, PhD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-143237

Published: 2020

Journal Articles

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Qunling Zhang, Jichuan Wu, Juan J. Gu, Yizhen Liu, Zuguang Xia, Lan Wang, Xiaonan Hong, Junning Cao

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141887

Published: 2020

Journal Articles

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

Juan J. Gu, MD PhD, Samuel J. Thompson, Cory Mavis, MSc, Matthew J. Barth, MD, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 5301.

https://doi.org/10.1182/blood-2019-129009

Published: 2019

Journal Articles

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Tara Daly, BS, Thomas Ippolito, MSc, Juan J. Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2019) 134 (Supplement_1): 5303.

https://doi.org/10.1182/blood-2019-129052

Published: 2019

Journal Articles

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

Juan J. Gu, MD PhD, Yizhen Liu, MD PhD, Jia Jin, Ling Yang, Zuguang Xia, Xiaojian Liu, Fangfang Lv, MD, Francisco J. Hernandez-Ilizaliturri, MD, Xiaonan Hong, Junning Cao, MD, Qunling Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 5233.

https://doi.org/10.1182/blood-2019-128878

Published: 2019

Journal Articles

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J. Gu, MD PhD, Michael Vacaro, Kris Attwood, PhD MS, Cory Mavis, MSc, Pallawi Torka, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2019) 134 (Supplement_1): 1629.

https://doi.org/10.1182/blood-2019-128512

Published: 2019

Journal Articles

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

Qunling Zhang, MD PhD, Juan J Gu, PhD, Cory Mavis, MSc, Ye Guo, MD, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 4212.

https://doi.org/10.1182/blood.V128.22.4212.4212

Published: 2016

Journal Articles

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Juan J Gu, PhD, Matthew J. Barth, MD, Qunling Zhang, MD PhD, Cory Mavis, MSc, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5378.

https://doi.org/10.1182/blood.V128.22.5378.5378

Published: 2016

Journal Articles

Itraconazole, an Oral Antifungal Drug, Inhibits Tumor Growth and Enhances Therapeutic Agent Activity in Double Hit Lymphoma

Juan J Gu, PhD, Lianjuan Yang, MD, Benjamin Jarmusz, Daniel Cress, Cory Mavis, MSc, Matthew J. Barth, MD, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2016) 128 (22): 5380.

https://doi.org/10.1182/blood.V128.22.5380.5380

Published: 2016

Journal Articles

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Thomas Ippolito, MS, Juan J Gu, PhD, Gregory Tang, Cory Mavis, MSc, Rodney R. Miles, MD PhD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2016) 128 (22): 5381.

https://doi.org/10.1182/blood.V128.22.5381.5381

Published: 2016

NARROW

Application of a Phenotype-Based Predictive Analytic in a Phase Ib Study of Selinexor and Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Prediction of Volasertib Sensitivity in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax Plus Azacitidine

A Phase 2 Study with Volasertib for Ven-HMA Relapsed/Refractory Acute Myeloid Leukemia Patients Guided By a Predictive Precision Medicine Platform

Clinical Predictors of Central Nervous System Relapse in Primary Breast Diffuse Large B-Cell Lymphoma

Targeting BCL-XL to Overcome Anti-CD20 Antibodies and Venetoclax Resistance in Pre-Clinical Model of Diffuse Large B Cell Lymphoma

Effect of Mcl-1 Inhibitor, AMG-176, on T Cell Quality and Function

Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma

Determinants of COVID-19 Vaccine Response in Patients with Lymphoma on B Cell Directed Therapy

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies

Potentiate Immune Activation and Function By Targeting Inhibitor of Apoptosis Proteins (IAPs) in Relapse/Refractory DLBCL

BRD4 Inhibitors Enhance the Anti-Tumor Activity of Targeted Therapy in Chronic Lymphocytic Leukemia

Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma

Targeting MDM2 and XIAP By Idasanutlin in Diffuse Large B-Cell Lymphoma

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post- the Incorporation of Rituximab to Standard CHOP Chemotherapy

BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance

JQ1, a c-MYC Inhibitor Targets Hexokinase II and Enhances the Cytotoxic Effects of Chemotherapeutic Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Itraconazole, an Oral Antifungal Drug, Inhibits Tumor Growth and Enhances Therapeutic Agent Activity in Double Hit Lymphoma

Targeting BET Bromodomains in Pre-Clinical Models of Burkitt Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only